1. CAS Reg. No. 142797-34-0. 2. CAS Reg. No. 65666-07-1. 3. CAS Reg. No. 36804-18-9. BAY 2666605 1 is a phosphodiesterase 3 (PDE3) inhibitor that is being developed to combat melanoma. It is active ...

Ensifentrine is billed as a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), and is thought to combine bronchodilator and anti-inflammatory properties in one ...

Get Instant Summarized Text (Gist) New inhibitors of the enzyme human 15-lipoxygenase-2 (h15-LOX-2) have been identified using computational tools and virtual screening. This enzyme is involved in ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

Data released from Phase 2 trials of Anktiva in patients with non-small-cell lung cancer, who did not respond to checkpoint inhibitors, showed median overall survival that was almost double that ...

In 2024, drugmakers delivered breakthrough treatments in conditions that had seen little progress for decades—and helped make existing therapies more accessible. Approved in July, Eli Lilly’s ...

Several observations from preclinical and short-term clinical studies support a role for sildenafil in the treatment of heart failure patients. The following discussion briefly considers each of ...